Skip to main content
NASDAQ:KPTI

Karyopharm Therapeutics News Headlines

$9.18
-0.13 (-1.40 %)
(As of 05/14/2021 01:43 PM ET)
Add
Compare
Today's Range
$8.89
$9.36
50-Day Range
$8.11
$11.11
52-Week Range
$7.78
$21.82
Volume63,483 shs
Average Volume2.45 million shs
Market Capitalization$689.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93

Headlines

Karyopharm Therapeutics (NASDAQ KPTI) News Headlines Today

SourceHeadline
Karyopharm Therapeutics (NASDAQ:KPTI)  Shares Down 2.4% Karyopharm Therapeutics (NASDAQ:KPTI) Shares Down 2.4%
americanbankingnews.com - May 14 at 1:11 PM
Tuesday 5/11 Insider Buying Report: KPTI, TUPTuesday 5/11 Insider Buying Report: KPTI, TUP
nasdaq.com - May 11 at 5:59 PM
Insider Buying: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) EVP Purchases 23,250 Shares of StockInsider Buying: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) EVP Purchases 23,250 Shares of Stock
americanbankingnews.com - May 11 at 12:12 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Up 4% Following Insider Buying ActivityKaryopharm Therapeutics (NASDAQ:KPTI) Stock Price Up 4% Following Insider Buying Activity
americanbankingnews.com - May 11 at 10:19 AM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Garen G. Bohlin Acquires 4,000 Shares of StockKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Director Garen G. Bohlin Acquires 4,000 Shares of Stock
americanbankingnews.com - May 10 at 8:58 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $15.00Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $15.00
americanbankingnews.com - May 10 at 11:02 AM
SVB Leerink Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $15.00SVB Leerink Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $15.00
americanbankingnews.com - May 10 at 11:02 AM
Some Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Analysts Just Made A Major Cut To Next Years EstimatesSome Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Analysts Just Made A Major Cut To Next Year's Estimates
finance.yahoo.com - May 9 at 12:54 PM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported And Analysts Have Been Cutting Their EstimatesKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported And Analysts Have Been Cutting Their Estimates
nasdaq.com - May 7 at 1:16 PM
Q2 2021 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Analyst (NASDAQ:KPTI)Q2 2021 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Analyst (NASDAQ:KPTI)
americanbankingnews.com - May 7 at 10:42 AM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to Post Q2 2021 Earnings of ($0.65) Per Share, Jefferies Financial Group ForecastsKaryopharm Therapeutics Inc. (NASDAQ:KPTI) to Post Q2 2021 Earnings of ($0.65) Per Share, Jefferies Financial Group Forecasts
americanbankingnews.com - May 6 at 7:44 AM
SVB Leerink Weighs in on Karyopharm Therapeutics Inc.s Q2 2021 Earnings (NASDAQ:KPTI)SVB Leerink Weighs in on Karyopharm Therapeutics Inc.'s Q2 2021 Earnings (NASDAQ:KPTI)
americanbankingnews.com - May 6 at 7:44 AM
Q2 2021 Earnings Forecast for Karyopharm Therapeutics Inc. Issued By Wedbush (NASDAQ:KPTI)Q2 2021 Earnings Forecast for Karyopharm Therapeutics Inc. Issued By Wedbush (NASDAQ:KPTI)
americanbankingnews.com - May 6 at 7:44 AM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Buy" from BrokeragesKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Buy" from Brokerages
americanbankingnews.com - May 5 at 6:48 AM
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call TranscriptKaryopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:35 PM
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $19.00Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $19.00
americanbankingnews.com - May 4 at 1:04 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $30.00Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $30.00
americanbankingnews.com - May 4 at 1:04 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly  Earnings ResultsKaryopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results
americanbankingnews.com - May 4 at 8:22 AM
Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call TranscriptKaryopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 3 at 6:23 PM
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $15.00 at SVB LeerinkKaryopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $15.00 at SVB Leerink
americanbankingnews.com - May 3 at 2:34 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Sets New 52-Week Low on Analyst DowngradeKaryopharm Therapeutics (NASDAQ:KPTI) Sets New 52-Week Low on Analyst Downgrade
americanbankingnews.com - May 3 at 1:44 PM
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue EstimatesKaryopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 3 at 1:22 PM
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive OfficerKaryopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
finance.yahoo.com - May 3 at 8:21 AM
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company ProgressKaryopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
finance.yahoo.com - May 3 at 8:21 AM
$26.50 Million in Sales Expected for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) This Quarter$26.50 Million in Sales Expected for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) This Quarter
americanbankingnews.com - May 2 at 1:02 AM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Announce Earnings of -$0.70 Per ShareKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Announce Earnings of -$0.70 Per Share
americanbankingnews.com - April 30 at 8:16 PM
Earnings Preview: Karyopharm TherapeuticsEarnings Preview: Karyopharm Therapeutics
benzinga.com - April 30 at 4:22 PM
Jefferies Financial Group Weighs in on Karyopharm Therapeutics Inc.s Q1 2021 Earnings (NASDAQ:KPTI)Jefferies Financial Group Weighs in on Karyopharm Therapeutics Inc.'s Q1 2021 Earnings (NASDAQ:KPTI)
americanbankingnews.com - April 30 at 6:26 AM
Karyopharm Therapeutics (KPTI) Set to Announce Quarterly Earnings on MondayKaryopharm Therapeutics (KPTI) Set to Announce Quarterly Earnings on Monday
americanbankingnews.com - April 29 at 8:16 AM
BRIEF-Karyopharm Announces European Medicines Agencys Validation Of Its Type Ii Variation Marketing Authorization Application For Nexpovio® (Selinexor) In Combination With ...BRIEF-Karyopharm Announces European Medicines Agency's Validation Of Its Type Ii Variation Marketing Authorization Application For Nexpovio® (Selinexor) In Combination With ...
msn.com - April 26 at 3:14 PM
If You Had Bought Karyopharm Therapeutics (NASDAQ:KPTI) Shares A Year Ago You Would Be Down 61%If You Had Bought Karyopharm Therapeutics' (NASDAQ:KPTI) Shares A Year Ago You Would Be Down 61%
nasdaq.com - April 24 at 11:24 AM
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 3.2%Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 3.2%
americanbankingnews.com - April 23 at 1:36 PM
Karyopharm Therapeutics (NASDAQ:KPTI) Hits New 52-Week Low at $9.34Karyopharm Therapeutics (NASDAQ:KPTI) Hits New 52-Week Low at $9.34
americanbankingnews.com - April 19 at 12:48 PM
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future OncologyKaryopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
finance.yahoo.com - April 19 at 8:32 AM
Market Sentiment Around Loss-Making Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Market Sentiment Around Loss-Making Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
finance.yahoo.com - April 14 at 9:18 AM
Karyopharm Stock Is Trading Higher After Chinas NMPA Signs Off Early-Stage ATG-019 Study In Cancer SettingsKaryopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
finance.yahoo.com - April 6 at 1:16 PM
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkins LymphomaAntengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
markets.businessinsider.com - April 6 at 8:15 AM
Karyopharm Therapeutics Stock Appears To Be Possible Value TrapKaryopharm Therapeutics Stock Appears To Be Possible Value Trap
finance.yahoo.com - April 5 at 5:48 PM
Karyopharms Selinexor Receives Conditional Approval In Europe For Type Of Blood CancerKaryopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer
markets.businessinsider.com - March 29 at 2:45 PM
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple MyelomaKaryopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
finance.yahoo.com - March 29 at 2:44 PM
Expanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class TherapeuticsExpanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class Therapeutics
finance.yahoo.com - March 10 at 1:46 PM
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by Chinas NMPAAntengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
markets.businessinsider.com - February 23 at 7:41 PM
Karyopharm Announces Upcoming Virtual Investor Conference ParticipationKaryopharm Announces Upcoming Virtual Investor Conference Participation
finance.yahoo.com - February 17 at 7:45 PM
Analysts Have Lowered Expectations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Latest ResultsAnalysts Have Lowered Expectations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Latest Results
finance.yahoo.com - February 13 at 1:08 PM
Karyopharm Therapeutics EPS in-line, beats on revenueKaryopharm Therapeutics EPS in-line, beats on revenue
seekingalpha.com - February 12 at 8:06 PM
News Flash: 9 Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Earnings Are Under ThreatNews Flash: 9 Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Earnings Are Under Threat
nasdaq.com - February 12 at 3:06 PM
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue EstimatesKaryopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - February 11 at 1:01 PM
Recap: Karyopharm Therapeutics Q4 EarningsRecap: Karyopharm Therapeutics Q4 Earnings
finance.yahoo.com - February 11 at 1:01 PM
JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovios Footprint, OTLK On TrackJNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track
markets.businessinsider.com - February 5 at 3:04 AM
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell LymphomaKaryopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
finance.yahoo.com - February 4 at 12:00 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.